Related Experiment Videos
Technology insight: ablative techniques for Barrett's esophagus--current and emerging trends
1Gastroenterology and Colon Cancer Center, National Naval Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889-5600, USA. mhjohnston@bethesda.med.navy.mil
Nature Clinical Practice. Oncology
|September 1, 2005
Summary
New endoscopic ablative techniques offer alternatives for treating esophageal precancerous conditions like Barrett's esophagus. Further research is needed to determine the superiority and long-term effectiveness of these esophageal cancer treatments.
Area of Science:
- Gastroenterology
- Oncology
- Endoscopic Therapeutics
Background:
- Esophageal adenocarcinoma precursors, including Barrett's esophagus with dysplasia and early esophageal cancer, necessitate effective treatment options.
- Esophagectomy, while effective, carries significant morbidity and mortality risks.
- Limitations of current technologies drive interest in alternative treatments like mucosal ablation.
Purpose of the Study:
- To review emerging endoscopic mucosal ablative techniques for esophageal precancerous conditions.
- To compare the potential benefits and risks of various ablative methods against traditional treatments and disease progression.
Main Methods:
- Review of available endoscopic ablative techniques: photodynamic therapy, laser therapy, multipolar electrocoagulation, argon plasma coagulation, endoscopic mucosal resection, radiofrequency ablation, and cryotherapy.
- Analysis of ongoing comparative trials investigating the efficacy and safety of these techniques.
Main Results:
- Multiple endoscopic ablative techniques have been developed over the past two decades.
- The optimal ablative technique and its long-term outcomes, including cancer risk reduction and cost-effectiveness, are yet to be determined.
Conclusions:
- Endoscopic ablative techniques represent a promising alternative for managing Barrett's esophagus and early esophageal cancer.
- Further comparative studies are essential to establish the superiority, safety, and cost-effectiveness of these novel esophageal cancer therapies.